Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1615-2573
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation ; day:6 ; month:4 ; year:2020 ; pages:1-10
Heart and vessels ; (6.4.2020), 1-10
- Urheber
-
Murakawa, Yuji
Ikeda, Takanori
Ogawa, Satoshi
Kitazono, Takanari
Nakagawara, Jyoji
Minematsu, Kazuo
Miyamoto, Susumu
Hayashi, Yasuhiro
Kidani, Yoko
Okayama, Yutaka
Sunaya, Toshiyuki
Sato, Shoichiro
Yamanaka, Satoshi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00380-020-01587-z
- URN
-
urn:nbn:de:101:1-2020062302320334126350
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Murakawa, Yuji
- Ikeda, Takanori
- Ogawa, Satoshi
- Kitazono, Takanari
- Nakagawara, Jyoji
- Minematsu, Kazuo
- Miyamoto, Susumu
- Hayashi, Yasuhiro
- Kidani, Yoko
- Okayama, Yutaka
- Sunaya, Toshiyuki
- Sato, Shoichiro
- Yamanaka, Satoshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Risk factors of left atrial appendage thrombus in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial
Persistent or permanent atrial fibrillation is associated with severe cardioembolic stroke in patients with non-valvular atrial fibrillation
Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Risk factors of left atrial appendage thrombus in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial
Persistent or permanent atrial fibrillation is associated with severe cardioembolic stroke in patients with non-valvular atrial fibrillation
Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Risk factors of left atrial appendage thrombus in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial
Persistent or permanent atrial fibrillation is associated with severe cardioembolic stroke in patients with non-valvular atrial fibrillation
Cost-effectiveness analysis of anticoagulation options for non-valvular atrial fibrillation in Iran
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation